BGMA Emphasizes Benefits Of Competition After UK Hydrocortisone Fines
Generics Industry Association Responds To CMA Decision Over Illegal Deals
UK off-patent industry association the BGMA has responded to recent fines issued by competition regulator the CMA over illegal deals for hydrocortisone, highlighting the benefits of functioning generic competition as well as urging improvements to the UK’s pricing and reimbursement system to better recognize situations where supply is limited.
You may also be interested in...
Firms censured by the UK’s CMA competition regulator over illegal deals that drove up the price of hydrocortisone for around a decade have vowed to appeal against the decision and the imposition of fines totaling more than £260m.
When Mark Samuels took over leadership of the BGMA earlier this year, he was immediately forced to grapple with the twin pressures of Brexit and the COVID-19 pandemic. However, he tells Generics Bulletin in an exclusive interview, the UK off-patent industry has succeeded in maintaining supply against this difficult backdrop and deserves a more coherent government strategy to support the sector.
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.